Virax Biolabs (VRAX) Cash & Equivalents (2021 - 2023)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

Virax Biolabs (VRAX) has 3 years of Cash & Equivalents data on record, last reported at $9.4 million in Q1 2023.

• For Q1 2023, Cash & Equivalents rose 42888.32% year-over-year to $9.4 million; the TTM value through Mar 2023 reached $9.4 million, up 42888.32%, while the annual FY2023 figure was $9.4 million, 42888.32% up from the prior year.
• Cash & Equivalents reached $9.4 million in Q1 2023 per VRAX's latest filing, up from $21756.0 in the prior quarter.
• Across five years, Cash & Equivalents topped out at $9.4 million in Q1 2023 and bottomed at $17621.0 in Q1 2021.
• Average Cash & Equivalents over 3 years is $3.1 million, with a median of $21756.0 recorded in 2022.
• Peak YoY movement for Cash & Equivalents: grew 23.47% in 2022, then surged 42888.32% in 2023.
• A 3-year view of Cash & Equivalents shows it stood at $17621.0 in 2021, then grew by 23.47% to $21756.0 in 2022, then soared by 42888.32% to $9.4 million in 2023.
• Per Business Quant database, its latest 3 readings for Cash & Equivalents were $9.4 million in Q1 2023, $21756.0 in Q1 2022, and $17621.0 in Q1 2021.

Peer Comparison